Colonial Trust Advisors Cuts Holdings in Eli Lilly and Company (NYSE:LLY)

Colonial Trust Advisors decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,816 shares of the company's stock after selling 964 shares during the quarter. Eli Lilly and Company comprises 2.5% of Colonial Trust Advisors' investment portfolio, making the stock its 5th largest holding. Colonial Trust Advisors' holdings in Eli Lilly and Company were worth $28,422,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LLY. Highline Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after buying an additional 20 shares in the last quarter. Kovitz Investment Group Partners LLC raised its position in Eli Lilly and Company by 117.1% during the third quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock worth $41,000 after acquiring an additional 24,879 shares during the last quarter. FPC Investment Advisory Inc. lifted its holdings in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $48,000. Finally, Compass Financial Services Inc purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.1 %

LLY stock traded up $15.14 during mid-day trading on Monday, hitting $747.55. 1,488,839 shares of the company were exchanged, compared to its average volume of 3,379,060. The firm has a fifty day simple moving average of $837.05 and a 200 day simple moving average of $822.87. The company has a market capitalization of $708.80 billion, a PE ratio of 63.84, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. Wells Fargo & Company increased their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Morgan Stanley lowered their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Finally, Guggenheim reduced their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $1,012.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.